1-4 of 4
Graeme Walker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L. Dale, Scott Boiko, Tony Cheung, Jingwen Zhang, Shenghua Wen, Lillian Castriotta, Deborah Lawson, Michael Collins, Larry Bao, Miika J. Ahdesmaki, Graeme Walker, Greg O'Connor, Tammie C. Yeh, Alfred A. Rabow, Jonathan R. Dry, Corinne Reimer, Paul Lyne, Gordon B. Mills, Stephen E. Fawell, Michael J. Waring, Michael Zinda, Edwin Clark, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2563–2574.
https://doi.org/10.1158/1535-7163.MCT-16-0141
Published: 01 November 2016
View articletitled, AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Open the PDF for AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

Christine M. Chresta, Denis Alferez, Georgia Cerillo, Emma Still, Adina Hughes, Graeme Walker, Jane Kendrew, Claire Sadler, Jayne Harris, Iain Simpson, Andrew P. Thomas, Al Rabow, Robert Clarke, Sacha Howell, Graham Richmond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C135.
https://doi.org/10.1158/1535-7163.TARG-13-C135
Published: 01 November 2013
View articletitled, Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.
Journal Articles

Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.

Sarah A. Loddick, Sandra Brave, Hayley Campbell, Luke Gaughan, Jim Growcott, Natalie Lahan, Elizabeth Mouchet, Daniel O'Neill, Craig Robson, Fadhel Shaheen, Andrew Thomason, Dawn Trueman, Graeme Walker, Nigel Brooks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B107.
https://doi.org/10.1158/1535-7163.TARG-11-B107
Published: 12 November 2011
View articletitled, Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.
Journal Articles

Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

Susan Ashwell, Benjamin Caleb, Chun Deng, Stephen Green, Michael Grondine, Heather Haye, Candice Horn, James Janetka, Dongfang Liu, Elizabeth Mouchet, Shannon Ready, Judith Rosenthal, Christophe Queva, Karen Taylor, Adam Sheehy, Graeme Walker, Anne White, Sonya Zabludoff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A232.
Published: 01 November 2007
View articletitled, Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases